E
Eun Bong Lee
Researcher at New Generation University College
Publications - 277
Citations - 8627
Eun Bong Lee is an academic researcher from New Generation University College. The author has contributed to research in topics: Rheumatoid arthritis & Arthritis. The author has an hindex of 40, co-authored 253 publications receiving 6917 citations. Previous affiliations of Eun Bong Lee include Seoul National University & Seoul National University Hospital.
Papers
More filters
Journal ArticleDOI
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis
Ronald F van Vollenhoven,Roy Fleischmann,Stanley Cohen,Eun Bong Lee,Juan A. García Meijide,Sylke Wagner,Šárka Forejtová,Samuel H. Zwillich,David Gruben,Tamas Koncz,Gene V. Wallenstein,Sriram Krishnaswami,John D. Bradley,Bethanie Wilkinson +13 more
TL;DR: In patients with rheumatoid arthritis receiving background methotrexate, tofacitinib was significantly superior to placebo and was numerically similar to adalimumab in efficacy.
Journal ArticleDOI
Genome-wide association studies identify IL23R - IL12RB2 and IL10 as Behçet's disease susceptibility loci
Nobuhisa Mizuki,Akira Meguro,Masao Ota,Shigeaki Ohno,Tomoko Shiota,Tatsukata Kawagoe,Norihiko Ito,Jiro Kera,Eiichi Okada,Keisuke Yatsu,Yeong Wook Song,Eun Bong Lee,Nobuyoshi Kitaichi,Kenichi Namba,Yukihiro Horie,Mitsuhiro Takeno,Sunao Sugita,Manabu Mochizuki,Seiamak Bahram,Yoshiaki Ishigatsubo,Hidetoshi Inoko +20 more
TL;DR: A genome-wide association study in a Japanese cohort including 612 individuals with Behçet's disease and 740 unaffected individuals (controls) identified two suggestive associations on chromosomes 1p31.3 (IL23R-IL12RB2, rs12119179, P = 2.7 × 10−8) and 1q32.1 (IL10, rs1554286).
Journal ArticleDOI
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
Roy Fleischmann,Maurizio Cutolo,Mark C. Genovese,Eun Bong Lee,Keith S. Kanik,Seth Sadis,Carol A. Connell,David Gruben,Sriram Krishnaswami,Gene V. Wallenstein,Bethanie Wilkinson,Samuel H. Zwillich +11 more
TL;DR: Tofacitinib monotherapy at a dose of ≥3 mg twice a day was efficacious in the treatment of patients with active RA over 24 weeks and demonstrated a manageable safety profile.
Journal ArticleDOI
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Stanley Cohen,Yoshiya Tanaka,Xavier Mariette,Jeffrey R. Curtis,Eun Bong Lee,Peter Nash,Kevin L. Winthrop,Christina Charles-Schoeman,Krishan Thirunavukkarasu,Ryan DeMasi,Jamie Geier,Kenneth Kwok,Lisy Wang,R. Riese,Juergen Wollenhaupt +14 more
TL;DR: An integrated safety summary of tofacitinib from two phase I, nine phase II, six phase III and two long-term extension studies in adult patients with active RA is reported, finding AEs were generally stable over time and no new safety signals were observed compared with previous tofacItinib reports.
Journal ArticleDOI
Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.
Jürgen Wollenhaupt,Joel Silverfield,Eun Bong Lee,Jeffrey R. Curtis,Susan P. Wood,Koshika Soma,Chudy I. Nduaka,B. Benda,David Gruben,Hiroyuki Nakamura,Yoshihiro Komuro,Samuel H. Zwillich,Lisy Wang,R. Riese +13 more
TL;DR: Tofacitinib demonstrated consistent safety and persistent efficacy over 48 months in patients with RA, as measured by ACR response rate, DAS28-4-ESR, and HAQ-DI assessments.